Drug Profile
Research programme: RNA interference-based therapeutics - Kylin Therapeutics
Alternative Names: pRNAiLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Kylin Therapeutics
- Class RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 12 Nov 2010 Preclinical development is ongoing in USA for cancer
- 15 Jan 2009 pRNAi-based compounds are available for licensing for indications other than cancer (http://www.kylintherapeutics.com/index.php?id=71)